Clover Health Investments (CLOV) Cost of Revenue (2020 - 2026)

Clover Health Investments (CLOV) has 7 years of Cost of Revenue data on file, last reported at $589.6 million in Q1 2026.

• Quarterly Cost of Revenue rose 66.83% year-over-year to $589.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 64.86% YoY) and the FY2025 annual result came in at $1.6 billion, up 55.85% from the prior year.
• Cost of Revenue climbed to $589.6 million in Q1 2026, from $413.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $861.7 million in Q1 2022 to a low of -$1.6 billion in Q4 2022.
• A 5-year average of $303.6 million and a median of $274.8 million in 2023 frame the typical range for Cost of Revenue.
• The widest YoY moves for Cost of Revenue: up 301.89% in 2022, down 454.63% in 2022.
• Tracing CLOV's Cost of Revenue over 5 years: stood at -$1.6 billion in 2022, then surged by 115.94% to $249.8 million in 2023, then retreated by 2.69% to $243.0 million in 2024, then surged by 70.13% to $413.5 million in 2025, then surged by 42.6% to $589.6 million in 2026.
• The last three Cost of Revenue figures came in at $589.6 million (Q1 2026), $413.5 million (Q4 2025), and $423.5 million (Q3 2025), per Business Quant data.